Molecular diagnosis of nasopharyngeal carcinoma: A review

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 1, 1996, Pages 71-74

  Gan, Y Y ^a,d   Fones Tan, A ^a   Chan, S H ^b,c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Department of Microbiology ^*

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antibodies; Antigens; ELISA; Epstein Barr virus

Indexed keywords

VIRUS ANTIGEN; VIRUS PROTEIN;

ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; NASOPHARYNX TUMOR; REVIEW; SEROLOGY; VIROLOGY;

ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; SEROLOGIC TESTS; VIRAL PROTEINS;

EID: 0029686693     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Henle W, Henle G, Lennette E T. The Epstein-Barr virus. Sci Am 1979;241:48-59.
2. Chen H F, Sauter M, Haiss P, Muller L N. Immunological characterization of the Epstein-Barr virus phosphoprotein PP58 and deoxyribonuclease expressed in the baculovirus expression system. Int J Cancer 1991;48:879-88.
3. Chen H F, Kevan-Jah S, Suentzenich K O, Grasser F A, Mueller-Lantzsch N. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 1992; 190:106-15 .
4. Frech B, Zimber-Srrobl U, Yip T T C, Lau W H, Müeller-Lantzsch N. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 1993; 74:811-8.
5. Littler E, Baylis S A, Zeng Y, Conway M J, Mackett M, Arrand J R. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 1991; 337.685-9.
6. Ginsburg M. Antibodies against the large subunit of the EBV-encoded ribonucleotide reductase in patients with nasopharyngeal carcinoma. Int J Cancer 1990; 45:1048-53.
7. Fones-Tan A, Chan S H, Tsao S Y, Gan L H, Tan W H, Li B, et al. Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to EpsteinBarr virus ribonucleotide reductase in patients with nasopharyngeal carcinoma. Int J Cancer 1994; 59:739-42.
8. Chen J Y, Liu M Y, Hsu T Y, Cho S M, Yang C S. Use of bacterially expressed antigen for detection of antibodies to the EBV-specific deoxyribonuclease in sera from patients with nasopharyngeal carcinoma. J Virol Methods 1993; 45:49-66.
9. Mathew M, Cheng H M, Sam C K, Joab I, Prasad U, Cochet C. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol Immunuther 1994; 38:68-70.
10. Joab I, Nicolas J C, Schwaab G, de-The G, Clausse B, Perricaudet M, et al. Detection of anti-Epstein-Barr-virus trartsactivator (ZEBRA) antibodies m sera from patients with nasopharyngeal carcinoma. Int J Cancer 1991; 48:647-9.
11. Foong Y T, Cheng H M, Sam C K, Dillner J, Hinderer W, Prasad U Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 1990; 45:1061-4.
12. Pothen S, Cao T, Smith R, Levine P H, Levine A, Pearson G R. Identification of T- and B-cell epitopes associated with a restricted component of the Epstein-Barr virus-induced early antigen complex. Int J Cancer 1993;53:199-204
13. Zeng Y Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res 1985; 44.121-38.
14. Herde G, Henle W Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17:1-7.
15. Yao Q Y, Rowe M, Morgan A J, Sam C K, Prasad U, Dang H, et al. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization Int J Cancer 1991; 48:45-50.
16. Vroman B, Luka J, Rodriguez M, Pearson G R. Characterization of a major protein with a molecular weight of 160 000 associated with the viral capsid of Epstein-Barr virus. J Virol 1985; 53:107-13.
17. Uen W C, Luka J, Pearson G R. Development of an enzyme-linked immunosorbent assay (ELBA) for detecting IgA antibodies to the Epstein-Barr virus. Int J Cancer 1988; 41:479-82.
18. Van Grunsven W M J, Spaan W J M, Middeldorp J M. Localization and diagnostic application of immuno-dominant domains of the BKRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 1994, 170:13-9.
19. Pearson G R, Luka J, Petti L, Sample L, Birkenkach M, Braun D, et al. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. J Virol 1987; 160:151-61.
20. Baylis S A, Purifoy D J M, Littler E. High level expression of the Epstein-Barr virus alkaline deoxyribonuclease using a recombinant Baculovirus: Application to the diagnosis of nasopharyngeal carcinoma. Virology 1991; 181:390-4.
21. Cheng Y C. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1980; 77.6162-5.
22. Littler E, Newman W, Arrand J R. Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr Virus-coded thymidine kinase expressed in E. coli Int J Cancer 1990; 45:1028-32.
23. Turenne-Tessier M D, Ooka T, Calender A, De The G, Daillie J. Relationship between nasopharyngeal carcinoma and high antibody titers to Epstein Barr virus specific thymidine kinase. Int J Cancer 1989; 43:45-8.
24. Zhu X X, Zeng Y, Wolf H. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals. Int J Cancer 1986; 37:689-91.
25. Hille A, Klein K, Baumler S, Grasser F A, Müeller-Lantzsch N. Expression of Epstein-Barr virus nuclear antigen 1, 2A and 2B in the Baculovirus expression system: serological evaluation of human antibodies to these proteins J Med Virol 1993, 39:233-41.
26. Inoue N, Kuranari J, Harada S, Nakajima H, Ohbayashi M, Nakamura Y, et al. Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein Barr virus nuclear antigen 1. J Clin Microbiol 1992; 30 442-8
27. Lenette E T, Rymo L, Yadav M, Masucci G, Merk K, Timar L, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993; 29A:1584-9.
28. Cheng H M, Foong Y T, Mathew A, Sam C K, Dillner J, Prasad U. Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay. J Virol Methods 1993, 42:45-51.
29. Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 1988; 69:1217-28.
30. Tan R S, Li J S, Grill S P, Nutter L M, Cheng Y C Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma. Cancer Res 1986; 46:5024-8.
31. Gan Y Y, Fones-Tan A, Chan S H, Tsao S Y, Li B. Molecular cloning and expression of Epstein-Barr virus antigens in the lambda gt11 expression vector: antibodies towards proteins from the BORF2 and BKRF4 reading frames in NPC patients. Intervirology 1994; 37:233-5
32. Gorgievski-Hrisoho M, Hinderer W, Nebel-Schickel H, Horn J, Vornhagen R, Sonneborn H H, et al. Serodiagnosis of infectious mononucleosis by using recombinant Epstein Barr virus antigens and enzyme-linked immunosorbent assay technology J Clin Microbiol 1990; 28.2305-11.